Company InMed Pharmaceuticals Inc Deutsche Boerse AG
Equities
CA13764X1069
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- EUR | - |
May. 14 | Earnings Flash (INM) INMED PHARMACEUTICALS Posts Q3 Revenue $1.2M | MT |
May. 14 | InMed Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024 | CI |
Business Summary
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
BayMedica
100.0
%
| 1 | 100.0 % | 4 | 100.0 % | +279.61% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Canada
100.0
%
| 1 | 100.0 % | 4 | 100.0 % | +279.61% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Eric Adams
CEO | Chief Executive Officer | 61 | 16-06-15 |
Chief Operating Officer | - | 18-11-04 | |
Colin Clancy
IRC | Investor Relations Contact | - | - |
Gerard Griffin
SAM | Sales & Marketing | - | 22-01-31 |
Eric Hsu
PRN | Corporate Officer/Principal | - | 18-03-12 |
General Counsel | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Janet Grove
BRD | Director/Board Member | 57 | 22-02-10 |
Eric Adams
CEO | Chief Executive Officer | 61 | 16-06-15 |
Andrew Hull
CHM | Chairman | 61 | 16-09-11 |
Bryan Baldasare
BRD | Director/Board Member | 58 | 22-05-11 |
Nicole Lemerond
BRD | Director/Board Member | 48 | 22-08-07 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 8,357,956 | 8,275,427 ( 99.01 %) | 0 | 99.01 % |
Company contact information
InMed Pharmaceuticals, Inc.
815 West Hastings Street Suite 310
V6C 1B4, Vancouver
+604 669 7207
http://www.inmedpharma.comSector
Sales per Business
1st Jan change | Capi. | |
---|---|---|
+18.34% | 125B | |
+15.06% | 108B | |
-6.39% | 23.64B | |
+2.39% | 22.39B | |
-12.11% | 17.78B | |
-41.64% | 16.43B | |
-12.07% | 16.34B | |
+1.05% | 13.56B | |
+25.87% | 11.59B |
- Stock Market
- Equities
- INM Stock
- Stock
- Company InMed Pharmaceuticals Inc